Teprotumumab for Optic Neuropathy in Thyroid Eye Disease

JAMA Ophthalmol. 2021 Feb 1;139(2):244-247. doi: 10.1001/jamaophthalmol.2020.5296.

Authors

Dane H Slentz^{1

2}, Terry J Smith^{1

3}, Denise S Kim¹, Shannon S Joseph¹

Affiliations

¹ W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor.
² now with the Medical Eye Center, Manchester, New Hampshire.
³ Division of Metabolism and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.

PMID: 33270090
DOI: 10.1001/jamaophthalmol.2020.5296

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Graves Ophthalmopathy / complications
Graves Ophthalmopathy / diagnosis
Graves Ophthalmopathy / drug therapy*
Humans
Male
Middle Aged
Optic Nerve Diseases / diagnosis
Optic Nerve Diseases / drug therapy*
Optic Nerve Diseases / etiology
Remission Induction
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
teprotumumab